4[1]Cunha BA.The atypical pneumonias:clinical diagnosis and importance[J].Clin Microbiol Infect,2006,12(Suppl 3):12-24.
5[2]Vervloet LA,Marguet C,Camargos PA.Infection by Mycoplasma pneumoniae and its importance as an etiological agent in childhood community-acquired pneumonias[J].Braz J Infect Dis,2007,11(5):507-514.
6[3]Blasi F,Tarsia P,Aliberti S,et al.Chlamydia pneumoniae and Mycoplasma pneumoniae[J].Semin Respir Crit Care Med,2005,26 (6):617-624.
7[4]Miravitlles M.Moxifloxacin in respiratory tract infections[J].Expert Opin Pharmacother,2005,6(2):283-293.
8[5]Weiss T,Shalit l,Blau H,et al.Anti-inflammatory effects of moxifloxacin on activated human monocytic cells:inhibition of NF-kappaB and mitogen-activated protein kinase activation and of synthesis of proinflammatory cytokines[J].Antimicrob Agents Chemother,2004,48(6):1974-1982.
9[10]Nisar N,Guleria R,Kumar S,et al.Mycoplasma pneumoniae and its role in asthma[J].Anim Health Res Rev,2006,7(1-2):13-29.
10[11]Narita M,Tanaka H.Cytokines involved in the severe manifestations of pulmonary diseases caused by Mycoplasma pneumoniae[J].Pediatr Pulmonol,2007,42(4):397.
